CN100445285C - 烟碱性乙酰胆碱受体配体 - Google Patents

烟碱性乙酰胆碱受体配体 Download PDF

Info

Publication number
CN100445285C
CN100445285C CNB2004800382369A CN200480038236A CN100445285C CN 100445285 C CN100445285 C CN 100445285C CN B2004800382369 A CNB2004800382369 A CN B2004800382369A CN 200480038236 A CN200480038236 A CN 200480038236A CN 100445285 C CN100445285 C CN 100445285C
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
oxygen
stereoisomer
acceptable salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800382369A
Other languages
English (en)
Chinese (zh)
Other versions
CN1902204A (zh
Inventor
格伦·厄恩斯特
威廉·弗里茨
罗伯特·雅各布斯
艾菲奥恩·菲利普斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1902204A publication Critical patent/CN1902204A/zh
Application granted granted Critical
Publication of CN100445285C publication Critical patent/CN100445285C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB2004800382369A 2003-12-22 2004-12-20 烟碱性乙酰胆碱受体配体 Expired - Fee Related CN100445285C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53164403P 2003-12-22 2003-12-22
US60/531,644 2003-12-22

Publications (2)

Publication Number Publication Date
CN1902204A CN1902204A (zh) 2007-01-24
CN100445285C true CN100445285C (zh) 2008-12-24

Family

ID=34710242

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800382369A Expired - Fee Related CN100445285C (zh) 2003-12-22 2004-12-20 烟碱性乙酰胆碱受体配体

Country Status (5)

Country Link
US (1) US20070244097A1 (https=)
EP (1) EP1699802A1 (https=)
JP (1) JP2007515480A (https=)
CN (1) CN100445285C (https=)
WO (1) WO2005061511A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
JP2011513461A (ja) * 2008-03-11 2011-04-28 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体モジュレーターとして有用な新規な１，４−ジアザ−ビシクロ［３．２．１］オクタン誘導体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679673A (en) * 1992-09-24 1997-10-21 The United States Of America, Represented By The Department Of Health And Human Services Aralkyl bridged diazabicycloalkane derivatives for CNS disorders
WO2000058311A1 (fr) * 1999-03-30 2000-10-05 Sanofi-Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonane-4-carboxylates et carboxamides, leur preparation et leur application en therapeutique
EP1231212B1 (en) * 2001-02-06 2006-12-20 Pfizer Products Inc. Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679673A (en) * 1992-09-24 1997-10-21 The United States Of America, Represented By The Department Of Health And Human Services Aralkyl bridged diazabicycloalkane derivatives for CNS disorders
WO2000058311A1 (fr) * 1999-03-30 2000-10-05 Sanofi-Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonane-4-carboxylates et carboxamides, leur preparation et leur application en therapeutique
EP1231212B1 (en) * 2001-02-06 2006-12-20 Pfizer Products Inc. Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders

Also Published As

Publication number Publication date
WO2005061511A1 (en) 2005-07-07
JP2007515480A (ja) 2007-06-14
US20070244097A1 (en) 2007-10-18
CN1902204A (zh) 2007-01-24
EP1699802A1 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
EP0885221B1 (en) Azabicyclic esters of carbamic acids useful in therapy
CN1325501C (zh) 杂环化合物
JP2006507241A (ja) ニコチン性アセチルコリン作用剤としてのビアリールジアザビシクロアルカンアミド
JP2007532637A (ja) α７ニコチン性アセチルコリン受容体に対する新規な２−（１−アザ−ビシクロ［２．２．２］オクタ−３−イル）−２，３−ジヒドロイソインドール−１−オン／５，６−ジヒドロ−フロ［２，３−ｃ］ピロール−４−オン誘導体リガンド
US20070249588A1 (en) Nicotinic Acetylcholine Receptor Ligands
CN100445285C (zh) 烟碱性乙酰胆碱受体配体
US20070191422A1 (en) Nicotinic acetylcholine receptor ligands
US20070270458A1 (en) Nicotinic Acetylcholine Receptor Ligands
JP2007511603A (ja) ４−置換イミダゾール類
WO2006065217A1 (en) Nicotinic acetycholine receptor ligands
JP2007511602A (ja) ５−置換イミダゾール類
WO2005030777A1 (en) Non-amide nonanes
HK1099652A (en) Nicotinic acetylcholine receptor ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1099652

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081224

Termination date: 20100120

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1099652

Country of ref document: HK